Nrf2 can bind to the AREs in proteasomal gene promoter, which plays important roles in the degradation of DRP1
Klein S, Nestor JJ, Harris MS, Suyundikov A, Casper R, Steele SM, et al
Product is not tested for safety and efficacy in food, drug, medical device, cosmetic, no express or implied authorization to use for any other purpose, including, without limitation, in vitro diagnostic purposes, for humans or animals or for commercial purposes
University of Toronto pharmaceutical policy expert Mina Tadrous estimates patients could see pricing as low as $100-$150 per month , representing approximately 35-50% of current Ozempic costs . Realistic Timeline: While the patent expired in early January 2026, experts caution that approval timelines remain uncertain